Literature DB >> 11156818

Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.

S Kapur1, P Roy, J Daskalakis, G Remington, R Zipursky.   

Abstract

OBJECTIVE: The authors added haloperidol, a potent D(2) blocker, to ongoing treatment with clozapine in patients with schizophrenia to determine the effects of this combination on dopamine D(2) receptor blockade, prolactin level, and extrapyramidal side effects.
METHOD: At baseline and 4-8 weeks after the addition of haloperidol (4 mg/day) to ongoing clozapine treatment, five patients were examined for prolactin elevation, extrapyramidal side effects, drug plasma levels, and D(2) receptor occupancy measured with [(11)C]raclopride and positron emission tomography imaging.
RESULTS: Adding haloperidol significantly increased D(2) receptor occupancy, from a mean of 55% to 79%, and significantly increased the prolactin level. One patient developed akathisia, and another manifested mild extrapyramidal side effects.
CONCLUSIONS: Adding a modest dose of haloperidol to clozapine results in the high D(2) receptor occupancy and sustained prolactin elevation usually associated with typical antipsychotics. These findings suggest that the lack of prolactin elevation associated with clozapine derives mainly from low D(2) receptor occupancy and not from the medication's effects on other receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156818     DOI: 10.1176/appi.ajp.158.2.311

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  11 in total

Review 1.  Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies.

Authors:  J Tauscher; S Kapur
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 3.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

Review 5.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

7.  How have developments in molecular imaging techniques furthered schizophrenia research?

Authors:  Judy L Thompson; Nina Urban; Anissa Abi-Dargham
Journal:  Imaging Med       Date:  2009-12-01

8.  Long-term antipsychotic polypharmacy: how does it start, why does it continue?

Authors:  Patrice Grech; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2012-02

9.  Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.

Authors:  Kimberly E Vanover; Robert E Davis; Yun Zhou; Weiguo Ye; James R Brašić; Lorena Gapasin; Jelena Saillard; Michal Weingart; Robert E Litman; Sharon Mates; Dean F Wong
Journal:  Neuropsychopharmacology       Date:  2018-10-26       Impact factor: 7.853

10.  Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009.

Authors:  Yu-Tao Xiang; Robert W Buchanan; Gabor S Ungvari; Helen F K Chiu; Kelly Y C Lai; You-Hong Li; Tian-Mei Si; Chuan-Yue Wang; Edwin H M Lee; Yan-Ling He; Shu-Yu Yang; Mian-Yoon Chong; Ee-Heok Kua; Senta Fujii; Kang Sim; Michael K H Yong; Jitendra K Trivedi; Eun-Kee Chung; Pichet Udomratn; Kok-Yoon Chee; Norman Sartorius; Chay-Hoon Tan; Naotaka Shinfuku
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.